As an example, breast cancer cells with high HER-2 levels (known as HER-2 positive) have a tendency to grow and spread quickly, but they also respond better to HER-2 protein-targeted therapy, e.g., anti-HER-2 monoclonal antibodies. This evidence concerns the gene ERBB2 and breast cancer.